Vasculitis & polymyalgia rheumatica
Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway
Main finding · MalignancyResult — go to the resultHazard ratio 0.94 95% CI 0.73–1.21Authors' conclusion
In this long-term follow-up of a population-based PMR inception cohort, we found no excess malignancy risk at any time from PMR diagnosis through the end of life.
Study context
- Population
- All incident polymyalgia rheumatica (PMR) cases in Aust-Agder County, Norway, 1987–1997, diagnosed clinically by rheumatologists (mean age 72 years; 67.6% female)matched cohort
- Participants
- 296 vs 4,440
- Exposure
- PMR vs matched random comparators
- PMRn = 296
- Comparatorsn = 4,440reference
- Outcome
- Malignancy risk (first cancer diagnosis, Cancer Registry of Norway)
- Follow-up
- Lifetime ( to 31 December 2024)
Methodological detailsprospective, inception cohort, matched by age, sex and residency to 15 random comparators, Cox regression stratified on matched groups, 95.6% deceased by 31 December 2024
- Prospective
- Inception cohort
- Matched by age, sex and residency to 15 random comparators
- Cox regression stratified on matched groups
- 95.6% deceased by 31 December 2024
Main finding
Malignancy
Hazard ratio
0.94
95% CI 0.73–1.21
Events by group
PMRvs Comparators
HR 0.94 (95% CI 0.73–1.21)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Median follow-up
Malignancy by cancer type and by time since diagnosis
- No significant excess risk in separate analyses by cancer type or by time since diagnosis
Original publication
Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway. Rheumatology (Oxford). Published 9 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →